AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Atlantic Sapphire

Investor Presentation Feb 7, 2022

3543_rns_2022-02-07_25189617-7ee7-46c4-9331-be46b8227325.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Monthly Update – January 2022 February 7, 2022

IMPORTANT INFORMATION

IMPORTANT INFORMATION

This presentation (the "Presentation") has been produced by Atlantic Sapphire ASA (the "Company") exclusively for information purposes. This Presentation has not been approved, reviewed or registered with any public authority or stock exchange. This Presentation is not a prospectus and does not contain the same level of information as a prospectus. This Presentation is strictly confidential and may not be disclosed, in whole or in part, or summarized or otherwise reproduced, distributed or referred to, in whole or in part, without prior written consent of the Company. To the best of the knowledge of the Company and its Board of Directors, the information contained in this Presentation is in all material respect in accordance with the facts as of the date hereof, and contains no material omissions likely to affect its import.

This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates or intends to operate. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any of its subsidiary undertakings or any such person's officers or employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation to update any forward-looking statements or to conform these forward-looking statements to our actual results. Furthermore, information about past performance given in this Presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor any of its parent or subsidiary undertakings or any such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Actual experience may differ, and those differences can be material.

By reviewing this Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the businesses of the Company. This Presentation must be read in conjunction with the recent financial reports of the Company and the disclosures therein, as well as other public disclosures made by the Company. The distribution of this Presentation may in certain jurisdictions be restricted by law. Persons in possession of this Presentation are required to inform themselves about, and to observe, any such restrictions. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of this Presentation in any country or jurisdiction where specific action for that purpose is required.

This Presentation does not in itself constitute an offer to sell or form part of, and should not be construed as, an offer or invitation for the sale or subscription of, or a solicitation of an offer to buy or subscribe for, any shares or other securities in any jurisdiction, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.

This Presentation must be read in conjunction with the stock exchange release to which it is attached.

By reviewing this Presentation, you agree to be bound by the foregoing limitations.

This Presentation speaks as of February 7, 2022. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation. This Presentation shall be governed by Norwegian law, and any disputes relating to hereto is subject to the sole and exclusive jurisdiction of Norwegian courts, with Oslo District Court as legal venue.

Biological Performance

1 Biomass gain: Estimated net change in standing biomass in the period, adjusted for actual harvest volumes. Includes any culling or mortality.

Monthly Update – Jan '22

  • Performance of New Batches is in line budget expectations
  • The New Batches represented all of the net biomass gain in January 2022 compared to ~65% in December 2021
  • No maturation identified in New Batches

Focus Is On The New Batches

Biomass gain of Initial Batches vs. New Batches

US standing biomass overview1
as of January 31, 2022
Dec 31, 2021 Number Average
Weight
(grams)
Standing
Biomass
(kg)
Quarter
introduced
in start-feed
Comment
Initial batches2 375k 3,600 1,350,000 Groups exposed to uneven and suboptimal
conditions early in the cycle (chiller plant
breakdown, key water treatment tools missing)
B I 415k 1,200 500,000 Q4 '20 Stable conditions in line with plan
B II 500k 750 375,000 Q1 '21 Stable conditions in line with plan
B III 360k 400 144,000 Q2 '21 Stable conditions in line with plan
B IV 180k 230 42,000 Q2 '21 Fungus in hatchery stage, stable conditions
thereafter
Freshwater3 2,065k 60 124,000 Stable conditions in line with plan
Total 3,900k 2,535,000

1 The biomass overview is based on management estimates, and may change based on counting and weight sampling

2 Remaining batches introduced before mid-2020, that have not had stable conditions and therefore have mixed biological performance. To be harvested out by Q2 2022. 3 Excludes eggs in the hatchery

Biological Performance – JEA Index

Monthly Update – Jan '22

Comments

  • ~60% of the planned 'Ph. 1 steady state' standing biomass was stocked end-January
  • Average JEA index will increase gradually with growing biomass and replacement of Initial Batches with New Batches
  • 12 identical saltwater ongrowing systems
  • Budget JEA Index of 0.47 in Phase 1, which yields ~9,500t HOG of annual production

JEA Index To Increase With Growing Biomass

1 Johan E. Andreassen (JEA) Index on operational performance based on management estimates: kg RLW biomass gain per m3 per day

Price Achievement and Footprint

Monthly Update – Jan '22

1 Bluehouse Salmon store locator is updated 'live' at bluehousesalmon.com/where-to-buy/

2 Atlantic Sapphire 'Bluehouse premium' is superior, 3kg+ salmon on Return To Farm basis (excluding freight costs). Fishpool index price converted to USD using Norges Bank fx rates

Phase 2 Capex Status

Monthly Update – Jan '22

Capex Status as of December 31, 2021

  • \$225 million total budget
  • \$158 million committed, of which
    • \$34 million invested
    • \$124 million forecasted
  • \$67 million currently uncommitted
  • Phase 2 construction capex and speed remains solely at the Company's discretion until capex is committed

Schedule of Estimated Project Completion

  • Phase 2 construction progressing according to plan, expected to be ready for fish around YE '22
  • Forecasted amounts are based on expected cash flows from future bid packages

Phase 2 Construction Progressing According To Plan

Phase 2 Construction Photos

Monthly Update – Jan '22

Phase 2 Will Bring Total Annual Harvest Volume Capacity To 25,000t HOG

Other Updates

US offtake

  • Stable price achievement expected on the premium fish going forward
  • Higher percentage of downgrades and smaller sized fish expected to be harvested through Q1 2022
  • First promotions of 2022 completed with volume demand above expectations

Other

  • Continue to see high processing costs due to the use of external filleting
  • Announcement of inclusion of algal oil to feed, reducing the use of fish oil by 25%, making Atlantic Sapphire a 'net marine protein producer'

FIFF: The feed fish inclusion factor estimates the combined fishmeal and fish oil concentration of the feed on a dry-weight basis relative to the wild fish.

Talk to a Data Expert

Have a question? We'll get back to you promptly.